ACT Advisors’s Heron Therapeutics HRTX Stock Holding History

ACT Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.02K	Buy	+25,581	New	+$9.7K	﹤0.01%	83
2026 Q2	–	Sell	-28,443	Closed	-$22.8K	–	89
2026 Q1	$22.8K	Buy	28,443 +2,635	+10%	+$3.05K	0.01%	73
2025 Q4	$33.6K	Buy	25,808 +227	+0.9%	+$280	0.01%	61
2025 Q3	$32.2K	Sell	25,581 -74	-0.3%	-$117	0.01%	67
2025 Q2	$53.1K	Buy	25,655 +74	+0.3%	+$151	0.02%	56
2025 Q1	$56.3K	Hold	25,581	–	–	0.03%	53
2024 Q4	$39.1K	Hold	25,581	–	–	0.02%	49
2024 Q3	$50.9K	Buy	25,581 +3,436	+16%	+$8.2K	0.02%	50
2024 Q2	$77.5K	Hold	22,145	–	–	0.04%	44
2024 Q1	$61.3K	Hold	22,145	–	–	0.03%	43
2023 Q4	$37.6K	Buy	+22,145	New	+$24.4K	0.02%	42

Other funds holding HRTX

CPC

Congress Park Capital Saratoga Springs, New York $381M AUM 20.14% 1-Year Est. Return

Apeiron RIA Dallas, Texas $440M AUM 15.34% 1-Year Est. Return

DIM

DLK Investment Management Solana Beach, California $275M AUM 10.69% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

DDFG Inc Thousand Oaks, California $508M AUM 11.76% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $4.07B AUM 38.25% 1-Year Est. Return

Dynamic Advisor Solutions Phoenix, Arizona $3.52B AUM 15.33% 1-Year Est. Return

B. Riley Wealth Advisors Boca Raton, Florida $2.57B AUM 28.13% 1-Year Est. Return

ACT Advisors's HRTX Position: Q3 2026 in Review

ACT Advisors opened a new position in Heron Therapeutics (HRTX) in Q3 2026: 25,581 shares worth $8.02K. The stake represents ﹤0.01% of the portfolio and ranks #83 among its holdings. This is a return to the name: ACT Advisors previously reported a position in HRTX as recently as Q1 2026.

ACT Advisors first reported a position in HRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $77.5K in Q2 2024. 17 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.

ACT Advisors held 25,581 shares of Heron Therapeutics worth $8.02K as of Q3 2026.
Heron Therapeutics was a new ACT Advisors position in Q3 2026.
Heron Therapeutics made up ﹤0.01% of ACT Advisors's portfolio in Q3 2026, its #83 holding.
ACT Advisors first reported a position in Heron Therapeutics in Q4 2023 and has held it in 11 quarters since.
ACT Advisors's Heron Therapeutics position peaked at $77.5K in Q2 2024.
17 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.

Based on ACT Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.